Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation with intravenous immunoglobulin

P D Hall1

  • 1Department of Hospital Pharmacy Practice and Administration, College of Pharmacy, Medical University of South Carolina, Charleston 29425-0810.

Pharmacotherapy
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Focal nodular hyperplasia with calcification and ossification.

Pathology·2001
Same author

Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.

Clinical immunology (Orlando, Fla.)·2001
Same author

Influence of intestinal flora on the development of fibrosis and cirrhosis in a rat model.

Journal of gastroenterology and hepatology·2000
Same author

Development of CPR security using impact analysis.

Proceedings. AMIA Symposium·2000
Same author

Electrolytic treatment of colorectal liver tumour deposits in a rat model: a technique with potential for patients with unresectable liver tumours.

Digestive diseases (Basel, Switzerland)·2000
Same author

Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.

Toxicology and applied pharmacology·1999
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Intravenous immunoglobulin (IVIG) shows promise for autoimmune disorders by modulating immune cells and blocking receptors. Further clinical trials are needed to confirm its efficacy beyond primary immunodeficiencies.

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Therapeutics

Background:

  • Intravenous immunoglobulin (IVIG) has been used for over a decade to treat primary immunodeficiencies.
  • IVIG exhibits immunomodulatory effects, suggesting potential in autoimmune disorder management.
  • Understanding these mechanisms provides a rationale for exploring IVIG in autoimmune conditions.

Purpose of the Study:

  • To review the immunomodulatory effects of IVIG.
  • To explore the potential application of IVIG in managing autoimmune disorders.
  • To summarize existing evidence and identify the need for further research.

Main Methods:

  • Review of existing literature on IVIG's mechanisms of action.
  • Analysis of studies demonstrating IVIG's effects in various autoimmune conditions.

Related Experiment Videos

  • Identification of disorders where IVIG has shown activity, including idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, and Kawasaki disease.

    • Main Results:

    • IVIG can block Fc receptors on phagocytes.
    • IVIG interacts with the idiotype-anti-idiotype network.
    • IVIG modulates T lymphocytes, B lymphocytes, natural killer cells, and complement activity.

    Conclusions:

    • IVIG possesses significant immunomodulatory properties.
    • Evidence suggests IVIG's utility in several autoimmune disorders.
    • Controlled clinical trials are essential to validate initial findings and establish IVIG's role in autoimmune disease treatment.